Skip to main content

Table 3 Subtype analysis.

From: SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates

 

Histology

Tumor Stage

Adeno-carcinoma

Squamous Cell Carcinoma

NSCLC NOS

SCLC

Other/Unknown

All

Stage I

10/32 (31%)

19/24 (79%)

3/3 (100%)

-/-

-/-

32/59 (54%)

Stage II

7/17 (41%)

20/21 (95%)

2/3 (67%)

2/2 (100%)

-/-

31/43 (72%)

Stage III

20/34 (59%)

36/45 (80%)

16/22 (73%)

6/6 (100%)

1/1 (100%)

79/108 (73%)

Stage IV

12/23 (52%)

6/9 (67%)

4/8 (50%)

20/21 (95%)

0/1 (0%)

42/62 (68%)

Stage unknown

2/3 (67%)

3/4 (75%)

1/1 (100%)

-/-

0/1 (0%)

6/9 (67%)

All

51/109 (47%)

84/103 (82%)

26/37 (70%)

28/29 (97%)

1/3 (33%)

190/281 (68%)

  1. Stage and histology specific performance of the SHOX2 DNA methylation biomarker in 523 bronchial aspirates from patients with suspected lung cancer.